2025

Therapeutic Action of Tumor-Specific Amplitude Modulated Radio Frequency Electromagnetic Fields in Fibrolamellar Carcinoma

Timeframe: 2025 – 2026 Goal: Investigate the applicability of using an FDA-approved device to treat fibrolamellar patients Principal Investigator: Hugo Jimenez, PhD Study overview: In this study, Dr. Jimenez and his team will conduct initial feasibility testing with a device that delivers low energy amplitude modulated 27.12 MHz radiofrequency electromagnetic fields (AM RF EMF) to …

Read more

Spatially resolving the tumor microenvironment of fibrolamellar carcinoma

Timeframe: 2025 – 2027 Goal: Advance understanding of FLC’s unique tumor microenvironment Principal Investigator: Praveen Sethupathy, PhD Study overview: Through this grant, Praveen Sethupathy, PhD, of Cornell University plans to outline the “spatial transcriptomics” of FLC. Dr. Sethupathy’s lab has been a leader in functional genomic studies, especially for liver and gastro-intestinal cancers. His group …

Read more

DT2216 in Combination with Irinotecan: A Phase 1 Study with a Phase 2 Feasibility Cohort for Fibrolamellar Carcinoma

Timeframe: 2025 – 2028 Goal: Provide the drug necessary to enable a FLC clinical trial Grantee: Dialectic Therapeutics, Inc. Principal Investigators of related clinical study: Dr. Allison O’Neill, Dana-Farber Cancer Institute and Dr. Michael Ortiz, Memorial Sloan Kettering Cancer Center Effort overview: This grant funds the manufacturing and distribution of an experimental drug, DT2216, for …

Read more